<DOC>
	<DOCNO>NCT00615563</DOCNO>
	<brief_summary>The primary objective trial ass presence susceptibility tipranavir ARVs HIV-1 isolate treatment experienced patient . The secondary objective examine clinician ' use HIV drug resistance test treatment experienced patient currently fail PI base HAART regimen .</brief_summary>
	<brief_title>Utilization HIV Drug Resistance Testing Treatment Experienced Patients ( UTILIZE Study )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion Patients meet follow inclusion criterion eligible participation study : 1 . Signed patient inform consent prior study participation . 2 . HIV1 infect male female ? 18 year age . 3 . Have confirm ( 2 consecutive ) HIV RNA ? 1000 copies/mL ( one result must within 3 month enrollment study ) . 4 . Current HAART regimen contain protease inhibitor ? 3 month . 5 . Physicians consider change patient ? HAART regimen . f. ) History treatment 2 protease inhibitor ( include current PI ) . Low dose ritonavir ( i.e. &lt; 400 mg. bid ) count one PIs . Exclusion criteria A patient follow criterion exclude participation study : 1 . ARV medication naive . 2 . Active opportunistic infection . c. ) Known suspect nonadherence current HAART regimen assess investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>